ArticleCureus2026
Comparison of Menstrual Bleeding and Dysmenorrhea Following Immediate Postpartum Insertion of Copper-T 380A and Cu 375 Intrauterine Contraceptive Devices: A Prospective Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Immediate postpartum intrauterine contraceptive device (PPIUCD) insertion is an effective method of long-acting reversible contraception. Differences in copper surface area and device design between Copper-T (Cu-T) 380A and Cu 375 may influence bleeding and pain profiles. Data in the immediate postpartum setting remains limited. Methods This prospective observational study compared postpartum women who received Cu-T 380A (n=150) with Cu 375 (n=150) as PPIUCD following vaginal or cesarean delivery. Participants were followed at six weeks and six months. The primary outcome was menstrual blood loss assessed using the Pictorial Blood Assessment Chart (PBAC) and dysmenorrhea assessed using the Visual Analog Scale (VAS). Secondary outcomes included expulsion, abnormal vaginal discharge, unintended pregnancy, removal, and satisfaction. Results Baseline characteristics were comparable between groups. At six weeks, PBAC and dysmenorrhea scores did not differ significantly. At six months, Cu-T 380A users demonstrated higher PBAC and dysmenorrhea scores compared with Cu 375 users (p < 0.001). The absolute difference in PBAC scores was modest but statistically significant, and median values in both groups remained below thresholds typically associated with heavy menstrual bleeding. Safety outcomes, expulsion rates, and satisfaction were similar between groups. Conclusion The present study highlights that although both the PPIUCD options Cu-T 380A and Cu 375 have good patient acceptability and high satisfaction scores, Cu-375 as a PPIUCD causes significantly less menstrual bleeding, as well as less severity and duration of dysmenorrhea, when compared to Cu-T 380A. Since complications at follow-up are a major determinant in PPIUCD acceptance, Cu-375 is a lucrative option for women opting for reversible contraception after delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.